Clinical Trial Matcher

NCT06961149

Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate

Recruiting · Not Applicable · Shandong University · registry updated 2025-05-07

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

Detection and removal of polyps during colonoscopy is crucial for the prevention of colorectal cancer. Indigo carmine spraying up to the colonic mucosa could probably increase the adenoma detection rate, but considering the long withdrawal time of the endoscope and the resulting increase in time and cost. Linked-color imaging (LCI) is a newly developed image-enhanced endoscopy technology. It relies on wave length optimization of three colors (red, green, and blue) to make the lesions appear fuller. LCI improves the visibility of colorectal adenomas and polyps and may increase the detection rate of lesions. In order to explore the clinical application value of Linked-color imaging endoscopy, we performed a prospective, randomized controlled trial to compare adenoma detection rate of Linked-color imaging endoscopy and indigo carmine chromoendoscopy.

Inclusion

  • Age between 45 and 85 years
  • Patients with a history of colorectal adenoma
  • Patients whose first-degree relatives have a history of colorectal cancer or colorectal adenoma
  • Patients with gastrointestinal symptoms (abdominal pain, bloody stool, chronic diarrhea or constipation, Unexplained anemia or weight loss;
  • Patients with positive Fecal Immunochemical Test

Exclusion

  • Patients with pregnancy, inflammatory bowel disease, familial adenomatosis polyposis, suspected CRC; intestinal obstruction, coagulopathy
  • Patients with aspirin, clopidogrel or other anticoagulants/ antiplatelet drugs intake within 7 days
  • Patents previous colorectal resection
  • Patients with failed cecal intubation
  • Patients with inadequate bowel preparation quality (BBPS≤5)
  • Patients who refuse to participate or to provide informed consent

Open NCT06961149 on ClinicalTrials.govAll conditions